STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 2, April-June 2020
SHORT REPORTS
CEFTOLOZANE/TAZOBACTAM AS A TREATMENT FOR MULTIDRUG-RESISTANT P. AERUGINOSA IN A VENTRICLE-PERITONEAL SHUNT
GÓMEZ DE RUEDA FÉLIX, CANCELA DÍEZ BÁRBARA, TENA SEMPERE MARÍA EUGENIA, CÁRDENAS ANTÓN MYRIAM, GÁLVEZ DEL POSTIGO ANTONIO


Ceftolozane-tazobactam (C-T) is a combination at fixed doses of a cephalosporin and a beta-lactamase inhibitor of recent introduction in infectious pathology, authorized so far for the treatment of serious urinary tract infections, intra-abdominal and recent- ly respiratory infections. However, it seems to have a special activity against extend- ed-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, except AmpC or carbapenemases (except OXA 48) that are resistant. This makes it a reserve therapy to treat infections by drug-resistant P. aeruginosa (DR-PSA), a very frequent germ and difficult to eradicate in our Intensive Care Units (ICU).
The main objective of this clinical case is to share our sentinel experience in the treatment of a cranial wound infection with central nervous system involve- ment by DR-PSA, consequence of collaboration between the ICU and the Hospi- tal Pharmacy Unit.

CEFTOLOZANE-TAZOBACTAM — CENTRAL NERVOUS SYSTEM (CNS) — DRUG-RESISTANT — INFECTION



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25